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S292 Poster Session IIirradiation based (TBI) reduced intensity conditioning regimens
for allogeneic hematopoietic cell transplant (alloHCT). We pres-
ent results of the first 10 patients receiving a novel conditioning
regimen comprising fludarabine 40 mg/m2/day  four, melpha-
lan 50 mg/m2  one and TBI 200 cGy  two fractions. The
goal of this reduced intensity regimen was to achieve complete
rapid complete donor lymphoid chimerism in order to promote
graft vs. malignancy effects without excess regimen related
toxicity.
Methods: Ten consecutive patients, six male and four female,
underwent reduced intensity conditioning followed by alloHCT.
The median age was 51.5 (range 5-71). Diagnoses and patient
numbers were myelodysplastic syndrome (MDS), n5 3,acute
myeloid leukemia (AML), n5 3, Non-Hodgkin lymphoma
(NHL), n5 3 and Diamond Blackfan anemia, n5 1. Stem cell
sources peripheral blood (PB), n5 8 and bone marrow, n5 2.
Donors were related n5 8 of which n were HLA matched
and unrelated, n5 4 which  were HLA matched at  loci.
Three patients were undergoing second transplants (second
allo n5 1) and prior autoHCT (n5 2). Three patients had un-
controlled malignancy at the time of transplant. The extent of
donor chimerism was assessed by flow-sorting PB for myeloid
(CD33) and lymphoid (CD3) markers followed by short tandem
repeat (STR) analysis.
Results: At a median follow up 88 days (range 14-171); nine of ten
recipients were alive at day 30. One patient died on day fifteen
post transplant with progressive disease. Six of nine patients achieved
complete donor lymphoid chimerism and seven of nine patients
achieved complete donor myeloid chimerism in peripheral blood
day 30. This is significantly faster than historical controls using
200 cGy based regimens. Of the three patients who had incomplete
donor chimerism, two had refractory malignancy (AML or MDS) at
the time of transplant and the third patient developed progressive
MDS soon after. Treatment relatedmortality at day 100 was ten per-
cent. One of the ten patients manifested grade 3-4 Bearman regimen
related toxicity.
Conclusions: Reduced intensity with Flu/Mel/TBI 400 is well tol-
erated and produces rapid donor chimerism in allogeneic stem cell
recipients.
Results
GradePatientFollow-
up
(days)Days
post
BMT% Donor
Lymphoid
Chimerism% Donor
Myeloid
Chimerism3/4
Bearman
ToxicityUncont-
rolled
Malignancy#1 128 30 100 100 No Yes
#2 58 27 100 100 No No
#3 104 30 100 100 No No
#4 98 34 100 100 No No
#5 77 33 94 75 No No
#6 171 27 95 95 Yes No
#7 78 34 100 100 No No
#8 100 30 100 100 No Yes
#9 30 30 92 100 No No
#10 14 died
day 15
NA NA Yes Yes364
A STEM CELL POTENCY, QUALITY AND RELEASE (PQR) ASSAY FOR UM-
BILICAL CORD BLOOD THAT IS COMPLIANT WITH REGULATORY GUIDE-
LINES
Rich, I.N., Hall, K., Harper, H. HemoGenix, Inc, Colorado Springs, CO
New guidelines and regulations in the U.S.A. and Europe will
require that the cell potency of cellular and gene therapy products
are determined prior to their intended use in the patient. Umbil-
ical cord blood (UCB) is a cellular therapeutic product whose po-
tency and release criteria will fall under these criteria. The presentparameters of total nucleated cell (TNC) count, viability, CD34
and CFU not only fall significantly short of what would be re-
quired, but are used post-processing, pre-cryopreservation rather
than post-thaw prior to transplantation. Furthermore, none of
these tests determine stem cell ‘‘quality’’ or potency, which is
a measure of stem cell engraftment potential (EP). The CFU as-
say, as used by the UCB community, measures the differentiation
(not proliferation) of GM progenitors, which have no stem cell
properties and therefore can only detect engraftment outcome,
i.e. time to neutrophil engraftment, but not EP. An in vitro, in-
strument-based, ATP bioluminescence potency, quality and re-
lease (PQR) assay that can be fully validated for the intended
use has been developed and tested. 24 UCB samples were tested
for proliferation status (‘‘quality’’) and potential (potency) of 2
stem cell populations, 1 primitive (HPP-SP) and the other mature
(CFC-GEMM), each at 3 cell doses, and the response compared
to the same cell populations from a UCB reference standard.
The results showed that the assay is .90% effective in predicting
EP. Testing a single stem cell population (CFC-GEMM) can lead
to a false interpretation, but a duel stem cell potency assay can
provide greater predictive value for short- and long-term EP.
Stem cell ‘‘quality’’ should also be determined using duel popula-
tions, since together with potency, acceptance limits for release
criteria can be defined. The PQR assay is a powerful and predic-
tive tool that, together with other assays, can provide the trans-
plantation decision-maker with information that has, until now,
not been possible.365
THIOTEPA (TT), BUSULFAN (BU), AND CLOFARABINE (CLO) AS A CONDI-
TIONING THERAPY FOR ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANT FOR PATIENTS WITH HIGH RISK MALIGNANCIES: EARLY
RESPONSE AND ENGRAFTMENT DATA
Worth, L.L.1, Andersson, B.S.2, Kazerooni, R.3, Petropoulos, D.1,
Kelly, S.S.1, Lee, D.A.1, Du, M.1, Madden, T.L.3, deLima, M.J.2,
Champlin, R.E.2, Cooper, L.J.N.1 1M.D. Anderson Cancer Center, Hous-
ton, TX; 2M.D. Anderson Cancer Center, Houston, TX; 3M.D. Anderson
Cancer Center, Houston, TX
Introduction: Fludarabine (F) and Busulfan (Bu) are commonly
used together in transplantation conditioning regimens. To im-
prove on this combination, we substituted Clofarabine (Clo) for
F for its improved antileukemic activity. In addition, we added
Thiotepa (TT) as a polyfunctional alkylating agent recognized
for its antileukemic activity and its ability to cross the blood
brain barrier. We investigated TT+ (IV) Bu + Clo as a condition-
ing regimen for advanced malignancies using a variety of stem
cell sources.
Methods: Patients (pts) received TT 5 mg/kg over 1 hr on d -8. Bu
was given IV over 3 h to a daily AUC of 5,000 mcMol-min +/-10%
on d -5 to -3. Clo 40 mg/m2 was infused over 1 hr daily on d -6 to -3.
All 9 pts are evaluable for engraftment and survival beyond d +30.M/
F: 4/5. Median age was 22 (range 6-60). Five pts had AML [relapse
refractory/Flt3+/3rd transplant, CR1 h/o leptomeningeal disease,
MDS/AML (CR2), CR4 (3rd BMT) and CR7 (3rd BMT)]. Others
hadT-cell PLL (2), ALL (CR3), CLL (3rd relapse-refr). GVHDpro-
phylaxis was tacrolimus and mini-MTX or tacrolimus and MMF
[cord blood (CB) recipients]. Those with one Ag-mism or unrelated
grafts received rabbit-ATG. Stem cell sources included cord (4 db
CB; 1 single CB); MUD-apheresis (2), MUD-BM (1), MSD-apher-
esis (1).
Results: All pts engrafted neutrophils at a median of 14 d (10-25),
and platelets at a median of 42 d (CB) and 12 d (PB/BM), respec-
tively. 8 of the 9 pts are $60 days post transplantation, and the re-
maining pt  30 days. Esophagitis (max grade 2) was the most
common regimen related toxicity (RRT).Transient,mild hyperbilir-
ubinemia from RRT occurred in 5 pts. (med 3.6 mg/dl; range
2 – 9.1). Deaths (2) were due to GVHD (d +56) and infection (d
+56). Two pts relapsed (d +59, d +87). PB microsatellite chimerism
around day +30 showed 100% donor-derived T cell and myeloid
cells in 8 pts. One had mixed chimerism (3% recipient T cells).
